Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572598 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study of 18F Fluoropaclitaxel (FPAC)
A Early Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT00572598 is a Early Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 6 participants.
The verdict
NCT00572598, a Early Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
Multidrug resistance (MDR) is a cause of treatment failure in many cancer patients. MDR refers to a phenotype whereby a tumor is resistant to a large number of natural chemotherapeutic drugs. Having prior knowledge of the presence of such resistance would decrease morbidity from unsuccessful therapy and allow for the selection of individuals who may benefit from co-administration of MDR inhibiting drugs. The Tc-99m labeled single photon emitting radiotracers sestamibi and tetrofosmin have shown some predictive value. However, positron-emitting (PET) radiotracers, which allow for dynamic, quantitative imaging, hold the promise of more accurate and specific identification of MDR tumors. Objective: To obtain human safety data, to demonstrate imaging feasibility with FPAC, to obtain human biodistribution and to obtain preliminary evidence of breast tumor uptake concordance with response to therapy.
Interventions
- DRUG 4- [F-18] fluoropaclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00572598
The ClinicalTrials.gov registry entry for NCT00572598 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 4- [F-18] fluoropaclitaxel is the first listed.
NCT00572598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00572598 about?
NCT00572598 is a clinical study titled "Pilot Study of 18F Fluoropaclitaxel (FPAC)". Multidrug resistance (MDR) is a cause of treatment failure in many cancer patients. MDR refers to a phenotype whereby a tumor is resistant to a large number of natural chemotherapeutic drugs. Having prior knowledge of the presence of such resistance would decrease morbidity from unsuccessful therapy...
What is the current status of trial NCT00572598?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2005-05. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00572598?
The interventions under investigation include: 4- [F-18] fluoropaclitaxel (DRUG).
Who is sponsoring clinical trial NCT00572598?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.